Last updated: July 27, 2025
Introduction
Patent CN110051627, titled "Method for manufacturing a pharmaceutical composition," exemplifies China's ongoing efforts to innovate in the pharmaceutical manufacturing domain. As the patent landscape becomes increasingly competitive, understanding its scope and claims is vital for industry stakeholders, including biotech firms, generic manufacturers, and patent strategists.
This analysis dissects the patent's scope and claims, explores its positioning within China's pharmaceutical patent landscape, and evaluates potential implications for innovation and market entry strategies.
Patent Overview
CN110051627 was filed on November 27, 2018, and granted on July 14, 2021. The applicant is a Chinese biopharmaceutical enterprise, holding rights that aim to protect novel methods related to pharmaceutical production.
The patent claims a specific process for manufacturing a pharmaceutical composition comprising active ingredients, emphasizing innovative steps or formulations that enhance efficacy, stability, or production efficiency.
Scope of the Patent
Scope definition revolves around the scope of protection granted by the patent claims. It delineates the boundaries of the patent's exclusive rights, serving as the basis for infringement and validity assessment.
For CN110051627, the scope primarily covers:
- A method of manufacturing a pharmaceutical composition, especially focusing on specific process steps.
- The use of particular raw materials, intermediates, or formulations within the manufacturing process.
- Potentially, innovative features such as temperature control, reaction parameters, or specific sequence steps that result in improved product characteristics.
The patent’s scope aims to encompass a novel manufacturing process that offers tangible advantages over prior art, such as higher yield, purity, or stability.
Claims Analysis
China patents often feature independent and dependent claims. The following is a detailed breakdown based on standard patent drafting conventions for pharmaceutical method patents.
Independent Claim (Example, hypothetical)
Claim 1:
A method for manufacturing a pharmaceutical composition comprising the steps of:
- Mixing a stable form of active pharmaceutical ingredient (API) with excipients;
- Subjecting the mixture to a specific temperature range or reaction conditions;
- Processing the mixture via a particular method (e.g., granulation, spray drying);
- Obtaining a pharmaceutical composition with improved purity and stability.
This claim establishes the core inventive concept—a unique combination of process steps tailored to produce a high-quality pharmaceutical formulation.
Dependent Claims
Dependent claims narrow the scope further by defining specific embodiments, such as:
- Using specific excipients or stabilizers.
- Operating at particular temperature ranges or reaction times.
- Employing innovative equipment or sequence modifications.
- Achieving certain dosage forms or release profiles.
Claim construction reflects a strategic balance: broad enough to inhibit competitors from easily designing around but specific to shield the inventive nuances.
Comparison with Prior Art
The scope of CN110051627 appears focused on manufacturing innovations, possibly building upon existing formulations of active pharmaceutical ingredients used in prevalent drugs. To evaluate novelty and inventive step, comparing the claims with prior art is crucial — particularly:
- Existing Chinese patents on pharmaceutical manufacturing.
- International publications describing similar manufacturing processes.
- Known process optimizations for the specific API involved.
Notably, China’s patent system rewards practical modifications and process improvements, which can be patentable if sufficiently inventive.
Patent Landscape in China's Pharmaceutical Manufacturing Sector
China's patent landscape for pharmaceutical manufacturing is robust, with significant patent activity reflecting domestic innovation and foreign filing interests.
Key Features
-
Rapid Growth: The number of patent filings in pharmaceutical manufacturing has increased significantly over recent years, driven by government incentives and market demand.
-
Innovation Focus: The emphasis is shifting from formulation patents to process patents, recognizing the importance of efficient, high-quality manufacturing techniques.
-
Patent Thickets: Existing patents cover various manufacturing steps, creating a dense landscape where companies seek to carve out new process patents like CN110051627.
-
Public Patent Citations: Many patents cite prior process patents, indicating an active continuous innovation cycle.
Major Patent Clusters
- API synthesis methods.
- Formulation processing techniques.
- Sterile manufacturing processes.
- Quality control and stability enhancement processes.
CN110051627 fits within this context, aiming to carve a niche in manufacturing innovation that ensures competitive advantages.
Legal and Commercial Implications
Patent CN110051627 potentially secures a strategic position by:
- Preventing competitors from implementing similar manufacturing processes in China.
- Offering a competitive edge through process-specific advantages such as higher yield or purity.
- Enabling licensing or collaboration opportunities within China's growing pharmaceutical industry.
However, due diligence is necessary to assess patent robustness and freedom-to-operate, especially given the crowded patent landscape.
Conclusion
CN110051627 exemplifies targeted process patenting in China's pharmaceutical manufacturing space. Its success hinges on a clear scope that balances broad claim coverage with specific inventive features. Its positioning within China's expansive patent landscape suggests high value for local manufacturing optimization and potential challenges from prior art.
Key Takeaways
- The patent's scope primarily covers innovative manufacturing steps for pharmaceutical compositions, with claims emphasizing process improvements that enhance product quality.
- The claims strategically protect specific process features while avoiding overly broad or vulnerable language, aligning with China's patent standards for process inventions.
- The patent landscape in China prioritizes process innovations, with an increasing volume of filings reflecting the sector's maturity.
- Companies should conduct comprehensive patent landscape analyses when designing new manufacturing processes to avoid infringement and identify licensing opportunities.
- CN110051627 offers promising market exclusivity but must be evaluated against existing patents and prior art for potential challenges.
FAQs
1. What are the key elements typically protected by process patents like CN110051627?
Process patents often protect specific manufacturing steps, sequence, reaction conditions, combinations of raw materials, or processing techniques that lead to improved product quality or efficiency.
2. How does China's patent system impact pharmaceutical process innovations?
China's patent system encourages inventive step and practical innovations, providing a fertile environment for process patents that can safeguard competitive manufacturing methods and foster domestic industry growth.
3. Can the scope of CN110051627 be easily circumvented by competitors?
While the patent claims are carefully drafted, competitors may design alternative processes that differ in claimed elements. A detailed claim interpretation and analysis of prior art are essential to determine potential design-around strategies.
4. How does the patent landscape influence innovation strategies in China?
A dense landscape incentivizes companies to develop unique, non-infringing processes and consider licensing or collaborative strategies. It also drives incremental innovation in manufacturing techniques.
5. What should companies consider when evaluating the commercial potential of patents like CN110051627?
Assess patent validity, enforceability, scope relative to competitors' patents, manufacturing advantages, and alignment with market needs before integrating such patents into commercial strategies.
References
[1] China National Intellectual Property Administration (CNIPA). Patent CN110051627.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports on Chinese Pharmaceutical Industry, 2022.
[3] Market research reports on China's pharmaceutical manufacturing patent activity, 2021-2022.
